The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

China’s biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. Read more at The Business Times.

Vaccinated Covid patients with acute kidney injury had better survival rates, required less dialysis, and faced fewer ...

The American College of Obstetricians and Gynecologists is urging insurers to continue covering vaccinations during pregnancy in an open letter signed by 30 prominent professional health organizations ...

Introduction The global bioconjugation market is witnessing robust growth, primarily driven by the expanding demand for targeted therapies and ...

The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has singled it out for scrutiny, clouding its prospects.